Compare Ferrari NV (RACE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Viatris Inc — how do they compare? Ferrari NV trades at $411.12 (market cap $71.13B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Ferrari NV is far larger — about 3.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| RACE | VTRS | |
|---|---|---|
Market Cap | $71.13B | $19.09B |
Sector | Consumer Cyclical | Health |
52-Week High | $504.09 | $17.86 |
52-Week Low | $314.63 | $9.49 |
Enterprise Value | $73.08B | $31.21B |
Dividend Yield | 1.04% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $405.94, down 0.98% on the day, with technical indicators showing a bearish trend while fundamentals remain strong. The company reported solid Q2 2026 earnings of $2.99 EPS, beating estimates, and maintains robust profitability with 22.25% net margins. Recent news highlights Ferrari's first electric vehicle selling for $40 million at auction, demonstrating brand strength. Analyst consensus remains bullish with a $462.67 price target representing 14% upside potential from current levels.
Ferrari presents a compelling growth story with premium valuation justified by strong fundamentals, though elevated multiples leave little room for execution missteps. Key risks include luxury market cyclicality and electric vehicle transition challenges, while institutional buying activity supports long-term confidence. The stock's current technical weakness may present entry opportunities for investors believing in the company's brand power and margin stability.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
